Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 0.26% | 178.60 | 0.7% | $1354.05m | |
| MRK | Merck & Co., Inc. | 1.88% | 94.39 | 0.7% | $1234.84m | |
| PFE | Pfizer Inc. | 1.90% | 52.62 | 0.9% | $1115.96m | |
| LLY | Eli Lilly & Co. | 1.33% | 331.54 | 1.1% | $1039.83m | |
| BMY | Bristol-Myers Squibb Co. | 0.94% | 76.67 | 1.0% | $1000.78m | |
| ABBV | AbbVie, Inc. | 0.39% | 154.53 | 1.9% | $963.97m | |
| AZN | AstraZeneca Plc | 1.20% | 66.30 | 1.0% | $476.64m | |
| SGEN | Seagen Inc. | 0.10% | 176.95 | 5.7% | $326.40m | |
| GSK | GSK Plc | 0.21% | 43.39 | 0.2% | $272.96m | |
| TPTX | Turning Point Therapeutics, Inc. | -0.11% | 75.07 | 0.0% | $199.07m | |
| HZNP | Horizon Therapeutics Plc | -0.01% | 82.76 | 5.4% | $174.09m | |
| NVS | Novartis AG | -0.56% | 83.81 | 0.2% | $171.31m | |
| MRTX | Mirati Therapeutics, Inc. | 1.56% | 73.09 | 1.6% | $153.18m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 0.45% | 151.40 | 8.1% | $150.98m | |
| NVO | Novo Nordisk A/S | -0.92% | 110.22 | 0.1% | $147.01m |
Company Profile
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.